Drugs / WBC100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07014449 | Nov 2024 → Jun 2026 overdue | acute myeloid leukemia | Hangzhou Weben Pharma Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05100251 | Dec 2021 → Jan 2026 | neoplasm | Zhejiang University | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WBC100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05100251 ↗ |
| Route | Oral | “WBC100 will be administered orally as capsules once daily in 28-day cycles.” NCT07014449 ↗ |
| Target | MYC | “a drug targeting c-myc” NCT05100251 ↗ |